tlr 8  (InvivoGen)

Journal: Histochemistry and Cell Biology

Article Title: Stage-specific expression of Toll-like receptors in the seminiferous epithelium of mouse testis

doi: 10.1007/s00418-024-02310-z

Figure Lengend Snippet: Expression pattern of TLR-12 in the cycle of seminiferous epithelium. Anti-TLR-12 (NBP2-24,833, Novus, 1/50) primary antibody was used for detection of cells expressing TLR-12. Immune-positive cells expressing TLR-12 ( a , b , c ) appear brown in color. TLR-12 is expressed in spermatocytes, round and elongated spermatids, endosomal compartments and acrosomes ( a , b , c ). Please note that acrosomes of round spermatids ( a , b ), endosomal compartments of both spermatocytes ( b , c ) and elongated spermatids ( c ) are immune positive. Please note that PAS staining on the corresponding sequential section (Supplementary Fig. ) indicates that TLR-12 is expressed at early stage of spermatogenesis. Arrow heads indicate immunopositivity at the acrosome. eSt elongated spermatid, Ec endosomal compartment, rSt round spermatid, Ser Sertoli cell, *spermatocytes, and arrows indicate spermatogonia

Article Snippet: Anti-TLR-1 (B-23, Sc-130896, Santa Cruz Biotechnology, 1/50), anti-TLR 2 (NB100-56720, Novus, 1/50), anti-TLR-3 (NB100-56571, Novus, 1/50), anti-TLR-4 (NB100- 56,566, Novus, 1/50), anti-TLR-5 (H-127, Sc-10742, Santa Cruz Biotechnology, 1/50), anti-TLR-6 (NBP1-54,336, Novus, 1/50), anti-TLR-7 (NB100-56682, Novus, 1/50), anti-TLR-8 (NBP2- 24,917, Novus, 1/50), anti-TLR-9 (NBP2-24,729, Novus, 1/50), anti-TLR-11 (NBP1-77,204, Novus, 1/50), anti-TLR-12 (NBP2-24,833, Novus, 1/50), and anti-TLR-13 (NBP2-24,539, Novus, 1/50) were used as primary antibodies.

Techniques: Expressing, Staining

Journal: Histochemistry and Cell Biology

Article Title: Stage-specific expression of Toll-like receptors in the seminiferous epithelium of mouse testis

doi: 10.1007/s00418-024-02310-z

Figure Lengend Snippet: Expression pattern of TLR-13 in the cycle of seminiferous epithelium. Anti-TLR-13 (NBP2-24,539, Novus, 1/50) primary antibody was used for detection of cells expressing TLR-13. Immune-positive cells expressing TLR-13 appear brown in color. TLR-13 is expressed only in elongated spermatids and residual bodies. Please note that the presence of two immune-positive residual bodies located at the luminal surface of the seminiferous of epithelium (arrows). Please note that PAS staining on the corresponding sequential section (Supplementary Fig. ) indicates that TLR-13 is expressed at early stage of spermatogenesis. eSt elongated spermatid, Rb residual body, rSt round spermatid, *spermatocytes

Article Snippet: Anti-TLR-1 (B-23, Sc-130896, Santa Cruz Biotechnology, 1/50), anti-TLR 2 (NB100-56720, Novus, 1/50), anti-TLR-3 (NB100-56571, Novus, 1/50), anti-TLR-4 (NB100- 56,566, Novus, 1/50), anti-TLR-5 (H-127, Sc-10742, Santa Cruz Biotechnology, 1/50), anti-TLR-6 (NBP1-54,336, Novus, 1/50), anti-TLR-7 (NB100-56682, Novus, 1/50), anti-TLR-8 (NBP2- 24,917, Novus, 1/50), anti-TLR-9 (NBP2-24,729, Novus, 1/50), anti-TLR-11 (NBP1-77,204, Novus, 1/50), anti-TLR-12 (NBP2-24,833, Novus, 1/50), and anti-TLR-13 (NBP2-24,539, Novus, 1/50) were used as primary antibodies.

Techniques: Expressing, Staining

Journal: PLOS Pathogens

Article Title: Peculiar transcriptional reprogramming with functional impairment of dendritic cells upon exposure to transformed HTLV-1-infected cells

doi: 10.1371/journal.ppat.1012555

Figure Lengend Snippet: a. Schematic representation of the experimental design. MDDCs were exposed to uninfected (Jurkat, green) or HTLV-1-infected T cells (C91-PL, blue) for 24h, before restimulation with LPS or R848 for an additional 24h. b. Flow cytometry analysis after CD11c and CD86 staining, in LPS- ( left ) or R848-restimulated MDDCs ( right ) pre-exposed to Jurkat (red) or C91-PL (dark blue) cells. Data are represented as the normalized MFI of CD86, with the MFI in restimulated Jurkat-pre-exposed MDDCs set to 100 (n = 30 or 10 independent experiments, respectively). Presented data are a subset of , respectively and were analysed with Kruskal-Wallis test or ordinary one-way ANOVA, respectively as described in and Tables c. Supernatant from the indicated cocultures was collected after LPS restimulation, and TNF-α ( left ) and IFN-I ( right ) concentrations were quantified for n = 3 or 10 independent experiments, respectively. Presented data are a subset of and were analysed with RM one-way ANOVA or ordinary one-way ANOVA, respectively as described in and Tables. d. Schematic drawing summarizing the results from Figs and . The drawing was created using BioRender.com .

Article Snippet: Toll-like receptor (TLR)-4 agonist (LPS, tlrl-3pelps; 1μg/mL) and TLR-7/8 agonist (R848, tlrl-r848; 3μg/mL) were purchased from Invivogen.

Techniques: Infection, Flow Cytometry, Staining

Journal: Journal of Clinical Medicine

Article Title: Analysis of Selected Toll-like Receptors in the Pathogenesis and Advancement of Non-Small-Cell Lung Cancer

doi: 10.3390/jcm13102793

Figure Lengend Snippet: Peripheral blood immunophenotype analysis and serum concentration of sTLRs of NSCLC patients and healthy volunteers.

Article Snippet: Commercially available kits were employed, with particular use of the Human TLR2 ELISA Kit (range: 109.4–7000 pg/mL; sensitivity 17 pg/mL), Human TLR3 ELISA Kit (range: 156–10,000 pg/mL; sensitivity 10 pg/mL), Human TLR4 ELISA Kit (range: 0.41–100 ng/mL; sensitivity 0.4 ng/well), (Abcam in Cambridge, UK,) and the Human Toll-Like Receptor 7 (TLR7) ELISA Kit (range: 10–3500 ng/L; sensitivity 5.32 ng/mL), Human Toll-Like Receptor 8 (TLR-8) ELISA Kit (range: 20–0.312 ng/mL; sensitivity 0.06 ng/mL), and Human Toll-Like Receptor 9 (TLR-9) ELISA Kit (range: 20–0.312 ng/mL; sensitivity 0.06 ng/mL) from MyBiosource in San Diego, CA, USA.

Techniques: Concentration Assay

Journal: Journal of Clinical Medicine

Article Title: Analysis of Selected Toll-like Receptors in the Pathogenesis and Advancement of Non-Small-Cell Lung Cancer

doi: 10.3390/jcm13102793

Figure Lengend Snippet: Graphical representation of the results regarding the evaluation of the percentage of TLR8- and TLR9-positive peripheral blood lymphocyte populations tested. ( A ) Percentage of CD4+TLR8+ lymphocytes; ( B ) Percentage of CD8+TLR8+ lymphocytes; ( C ) Percentage of CD19+TLR8+ lymphocytes; ( D ) Percentage of CD4+TLR9+ lymphocytes; ( E ) Percentage of CD8+TLR9+ lymphocytes; ( F ) Percentage of CD19+TLR9+ lymphocytes; * Statistically significant results are marked.

Article Snippet: Commercially available kits were employed, with particular use of the Human TLR2 ELISA Kit (range: 109.4–7000 pg/mL; sensitivity 17 pg/mL), Human TLR3 ELISA Kit (range: 156–10,000 pg/mL; sensitivity 10 pg/mL), Human TLR4 ELISA Kit (range: 0.41–100 ng/mL; sensitivity 0.4 ng/well), (Abcam in Cambridge, UK,) and the Human Toll-Like Receptor 7 (TLR7) ELISA Kit (range: 10–3500 ng/L; sensitivity 5.32 ng/mL), Human Toll-Like Receptor 8 (TLR-8) ELISA Kit (range: 20–0.312 ng/mL; sensitivity 0.06 ng/mL), and Human Toll-Like Receptor 9 (TLR-9) ELISA Kit (range: 20–0.312 ng/mL; sensitivity 0.06 ng/mL) from MyBiosource in San Diego, CA, USA.

Techniques:

Journal: Journal of Clinical Medicine

Article Title: Analysis of Selected Toll-like Receptors in the Pathogenesis and Advancement of Non-Small-Cell Lung Cancer

doi: 10.3390/jcm13102793

Figure Lengend Snippet: Analysis of the percentage of TLR occurrence on selected subpopulations of peripheral blood lymphocytes in patients with NSCLC compared to healthy volunteers, with particular emphasis on survival status.

Article Snippet: Commercially available kits were employed, with particular use of the Human TLR2 ELISA Kit (range: 109.4–7000 pg/mL; sensitivity 17 pg/mL), Human TLR3 ELISA Kit (range: 156–10,000 pg/mL; sensitivity 10 pg/mL), Human TLR4 ELISA Kit (range: 0.41–100 ng/mL; sensitivity 0.4 ng/well), (Abcam in Cambridge, UK,) and the Human Toll-Like Receptor 7 (TLR7) ELISA Kit (range: 10–3500 ng/L; sensitivity 5.32 ng/mL), Human Toll-Like Receptor 8 (TLR-8) ELISA Kit (range: 20–0.312 ng/mL; sensitivity 0.06 ng/mL), and Human Toll-Like Receptor 9 (TLR-9) ELISA Kit (range: 20–0.312 ng/mL; sensitivity 0.06 ng/mL) from MyBiosource in San Diego, CA, USA.

Techniques:

Journal: Journal of Clinical Medicine

Article Title: Analysis of Selected Toll-like Receptors in the Pathogenesis and Advancement of Non-Small-Cell Lung Cancer

doi: 10.3390/jcm13102793

Figure Lengend Snippet: Analysis of the TLR results obtained in patients with stage IA at the time of recruitment and death.

Article Snippet: Commercially available kits were employed, with particular use of the Human TLR2 ELISA Kit (range: 109.4–7000 pg/mL; sensitivity 17 pg/mL), Human TLR3 ELISA Kit (range: 156–10,000 pg/mL; sensitivity 10 pg/mL), Human TLR4 ELISA Kit (range: 0.41–100 ng/mL; sensitivity 0.4 ng/well), (Abcam in Cambridge, UK,) and the Human Toll-Like Receptor 7 (TLR7) ELISA Kit (range: 10–3500 ng/L; sensitivity 5.32 ng/mL), Human Toll-Like Receptor 8 (TLR-8) ELISA Kit (range: 20–0.312 ng/mL; sensitivity 0.06 ng/mL), and Human Toll-Like Receptor 9 (TLR-9) ELISA Kit (range: 20–0.312 ng/mL; sensitivity 0.06 ng/mL) from MyBiosource in San Diego, CA, USA.

Techniques:

Journal: Journal of Clinical Medicine

Article Title: Analysis of Selected Toll-like Receptors in the Pathogenesis and Advancement of Non-Small-Cell Lung Cancer

doi: 10.3390/jcm13102793

Figure Lengend Snippet: Analysis of the TLR results obtained in patients with stage IIIB at the time of recruitment and death.

Article Snippet: Commercially available kits were employed, with particular use of the Human TLR2 ELISA Kit (range: 109.4–7000 pg/mL; sensitivity 17 pg/mL), Human TLR3 ELISA Kit (range: 156–10,000 pg/mL; sensitivity 10 pg/mL), Human TLR4 ELISA Kit (range: 0.41–100 ng/mL; sensitivity 0.4 ng/well), (Abcam in Cambridge, UK,) and the Human Toll-Like Receptor 7 (TLR7) ELISA Kit (range: 10–3500 ng/L; sensitivity 5.32 ng/mL), Human Toll-Like Receptor 8 (TLR-8) ELISA Kit (range: 20–0.312 ng/mL; sensitivity 0.06 ng/mL), and Human Toll-Like Receptor 9 (TLR-9) ELISA Kit (range: 20–0.312 ng/mL; sensitivity 0.06 ng/mL) from MyBiosource in San Diego, CA, USA.

Techniques:

Journal: Journal of Clinical Medicine

Article Title: Analysis of Selected Toll-like Receptors in the Pathogenesis and Advancement of Non-Small-Cell Lung Cancer

doi: 10.3390/jcm13102793

Figure Lengend Snippet: Analysis of the TLR results obtained in patients with stage IIIC at the time of recruitment and death.

Article Snippet: Commercially available kits were employed, with particular use of the Human TLR2 ELISA Kit (range: 109.4–7000 pg/mL; sensitivity 17 pg/mL), Human TLR3 ELISA Kit (range: 156–10,000 pg/mL; sensitivity 10 pg/mL), Human TLR4 ELISA Kit (range: 0.41–100 ng/mL; sensitivity 0.4 ng/well), (Abcam in Cambridge, UK,) and the Human Toll-Like Receptor 7 (TLR7) ELISA Kit (range: 10–3500 ng/L; sensitivity 5.32 ng/mL), Human Toll-Like Receptor 8 (TLR-8) ELISA Kit (range: 20–0.312 ng/mL; sensitivity 0.06 ng/mL), and Human Toll-Like Receptor 9 (TLR-9) ELISA Kit (range: 20–0.312 ng/mL; sensitivity 0.06 ng/mL) from MyBiosource in San Diego, CA, USA.

Techniques:

Journal: Journal of Clinical Medicine

Article Title: Analysis of Selected Toll-like Receptors in the Pathogenesis and Advancement of Non-Small-Cell Lung Cancer

doi: 10.3390/jcm13102793

Figure Lengend Snippet: Analysis of the TLR results obtained in patients with stage IV at the time of recruitment and death.

Article Snippet: Commercially available kits were employed, with particular use of the Human TLR2 ELISA Kit (range: 109.4–7000 pg/mL; sensitivity 17 pg/mL), Human TLR3 ELISA Kit (range: 156–10,000 pg/mL; sensitivity 10 pg/mL), Human TLR4 ELISA Kit (range: 0.41–100 ng/mL; sensitivity 0.4 ng/well), (Abcam in Cambridge, UK,) and the Human Toll-Like Receptor 7 (TLR7) ELISA Kit (range: 10–3500 ng/L; sensitivity 5.32 ng/mL), Human Toll-Like Receptor 8 (TLR-8) ELISA Kit (range: 20–0.312 ng/mL; sensitivity 0.06 ng/mL), and Human Toll-Like Receptor 9 (TLR-9) ELISA Kit (range: 20–0.312 ng/mL; sensitivity 0.06 ng/mL) from MyBiosource in San Diego, CA, USA.

Techniques:

Journal: Journal of Clinical Medicine

Article Title: Analysis of Selected Toll-like Receptors in the Pathogenesis and Advancement of Non-Small-Cell Lung Cancer

doi: 10.3390/jcm13102793

Figure Lengend Snippet: ROC prognostic analysis.

Article Snippet: Commercially available kits were employed, with particular use of the Human TLR2 ELISA Kit (range: 109.4–7000 pg/mL; sensitivity 17 pg/mL), Human TLR3 ELISA Kit (range: 156–10,000 pg/mL; sensitivity 10 pg/mL), Human TLR4 ELISA Kit (range: 0.41–100 ng/mL; sensitivity 0.4 ng/well), (Abcam in Cambridge, UK,) and the Human Toll-Like Receptor 7 (TLR7) ELISA Kit (range: 10–3500 ng/L; sensitivity 5.32 ng/mL), Human Toll-Like Receptor 8 (TLR-8) ELISA Kit (range: 20–0.312 ng/mL; sensitivity 0.06 ng/mL), and Human Toll-Like Receptor 9 (TLR-9) ELISA Kit (range: 20–0.312 ng/mL; sensitivity 0.06 ng/mL) from MyBiosource in San Diego, CA, USA.

Techniques:

Journal: Journal of Clinical Medicine

Article Title: Analysis of Selected Toll-like Receptors in the Pathogenesis and Advancement of Non-Small-Cell Lung Cancer

doi: 10.3390/jcm13102793

Figure Lengend Snippet: Graphical representation of the ROC analysis of selected immunophenotype parameters of dead NSCLC and alive NSCLC patients: ( A ) ROC curve for TLR2-positive lymphocyte percentage; ( B ) ROC curve for the percentage of TLR3-positive lymphocytes; ( C ) ROC curve for the percentage of TLR4-positive lymphocytes; ( D ) ROC curve for the percentage of TLR7-positive lymphocytes; ( E ) ROC curve for the percentage of TLR8-positive lymphocytes; ( F ) ROC curve for the percentage of TLR9-positive lymphocytes. Abbreviations: CD—cluster of differentiation; TLR—Toll-like receptors; ROC—Receiver Operating Characteristic.

Article Snippet: Commercially available kits were employed, with particular use of the Human TLR2 ELISA Kit (range: 109.4–7000 pg/mL; sensitivity 17 pg/mL), Human TLR3 ELISA Kit (range: 156–10,000 pg/mL; sensitivity 10 pg/mL), Human TLR4 ELISA Kit (range: 0.41–100 ng/mL; sensitivity 0.4 ng/well), (Abcam in Cambridge, UK,) and the Human Toll-Like Receptor 7 (TLR7) ELISA Kit (range: 10–3500 ng/L; sensitivity 5.32 ng/mL), Human Toll-Like Receptor 8 (TLR-8) ELISA Kit (range: 20–0.312 ng/mL; sensitivity 0.06 ng/mL), and Human Toll-Like Receptor 9 (TLR-9) ELISA Kit (range: 20–0.312 ng/mL; sensitivity 0.06 ng/mL) from MyBiosource in San Diego, CA, USA.

Techniques: